These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 28947349)

  • 1. Contribution of inflammatory pathways to Fabry disease pathogenesis.
    Rozenfeld P; Feriozzi S
    Mol Genet Metab; 2017 Nov; 122(3):19-27. PubMed ID: 28947349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathogenesis and Molecular Mechanisms of Anderson-Fabry Disease and Possible New Molecular Addressed Therapeutic Strategies.
    Tuttolomondo A; Simonetta I; Riolo R; Todaro F; Di Chiara T; Miceli S; Pinto A
    Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epithelial-Mesenchymal Transition in Kidney Tubular Epithelial Cells Induced by Globotriaosylsphingosine and Globotriaosylceramide.
    Jeon YJ; Jung N; Park JW; Park HY; Jung SC
    PLoS One; 2015; 10(8):e0136442. PubMed ID: 26291612
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of lysosomal and extralysosomal globotriaosylceramide (Gb3) accumulations before the occurrence of typical pathological changes in the endomyocardial biopsies of Fabry disease patients.
    Hsu MJ; Chang FP; Lu YH; Hung SC; Wang YC; Yang AH; Lee HJ; Sung SH; Wang YF; Yu WC; Hsu TR; Huang PH; Chang SK; Dzhagalov I; Hsu CL; Niu DM
    Genet Med; 2019 Jan; 21(1):224-232. PubMed ID: 29875425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tissue and plasma globotriaosylsphingosine could be a biomarker for assessing enzyme replacement therapy for Fabry disease.
    Togawa T; Kawashima I; Kodama T; Tsukimura T; Suzuki T; Fukushige T; Kanekura T; Sakuraba H
    Biochem Biophys Res Commun; 2010 Sep; 399(4):716-20. PubMed ID: 20692233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fabry disease peripheral blood immune cells release inflammatory cytokines: role of globotriaosylceramide.
    De Francesco PN; Mucci JM; Ceci R; Fossati CA; Rozenfeld PA
    Mol Genet Metab; 2013 May; 109(1):93-9. PubMed ID: 23452955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucosylceramide synthase inhibition with lucerastat lowers globotriaosylceramide and lysosome staining in cultured fibroblasts from Fabry patients with different mutation types.
    Welford RWD; Mühlemann A; Garzotti M; Rickert V; Groenen PMA; Morand O; Üçeyler N; Probst MR
    Hum Mol Genet; 2018 Oct; 27(19):3392-3403. PubMed ID: 29982630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enzyme replacement therapy partially prevents invariant Natural Killer T cell deficiency in the Fabry disease mouse model.
    Macedo MF; Quinta R; Pereira CS; Sa Miranda MC
    Mol Genet Metab; 2012 May; 106(1):83-91. PubMed ID: 22425450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distributions of Globotriaosylceramide Isoforms, and Globotriaosylsphingosine and Its Analogues in an α-Galactosidase A Knockout Mouse, a Model of Fabry Disease.
    Sueoka H; Aoki M; Tsukimura T; Togawa T; Sakuraba H
    PLoS One; 2015; 10(12):e0144958. PubMed ID: 26661087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Substrate-specific gene expression profiles in different kidney cell types are associated with Fabry disease.
    Shin YJ; Jeon YJ; Jung N; Park JW; Park HY; Jung SC
    Mol Med Rep; 2015 Oct; 12(4):5049-57. PubMed ID: 26135632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Higher apoptotic state in Fabry disease peripheral blood mononuclear cells.: effect of globotriaosylceramide.
    De Francesco PN; Mucci JM; Ceci R; Fossati CA; Rozenfeld PA
    Mol Genet Metab; 2011 Nov; 104(3):319-24. PubMed ID: 21724436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences in cleavage of globotriaosylceramide and its derivatives accumulated in organs of young Fabry mice following enzyme replacement therapy.
    Kodama T; Tsukimura T; Kawashima I; Sato A; Sakuraba H; Togawa T
    Mol Genet Metab; 2017; 120(1-2):116-120. PubMed ID: 27756537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathology and pathogenic pathways in fabry nephropathy.
    Feriozzi S; Rozenfeld P
    Clin Exp Nephrol; 2021 Sep; 25(9):925-934. PubMed ID: 33768330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of Immunity in Fabry Disease and Hypertension: A Review of a Novel Common Pathway.
    Del Pinto R; Ferri C
    High Blood Press Cardiovasc Prev; 2020 Dec; 27(6):539-546. PubMed ID: 33047250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathogenic pathways of renal damage in Fabry nephropathy: interplay between immune cell infiltration, apoptosis and fibrosis.
    Bondar C; de Bolla MLA; Neumann P; Pisani A; Feriozzi S; Rozenfeld PA
    J Nephrol; 2024 Apr; 37(3):625-634. PubMed ID: 38512375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Globotriaosylceramide is correlated with oxidative stress and inflammation in Fabry patients treated with enzyme replacement therapy.
    Biancini GB; Vanzin CS; Rodrigues DB; Deon M; Ribas GS; Barschak AG; Manfredini V; Netto CB; Jardim LB; Giugliani R; Vargas CR
    Biochim Biophys Acta; 2012 Feb; 1822(2):226-32. PubMed ID: 22085605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced glucosylceramide in the mouse model of Fabry disease: correction by successful enzyme replacement therapy.
    Quinta R; Rodrigues D; Assunção M; Macedo MF; Azevedo O; Cunha D; Oliveira P; Sá Miranda MC
    Gene; 2014 Feb; 536(1):97-104. PubMed ID: 24334116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A simple method for quantification of plasma globotriaosylsphingosine: Utility for Fabry disease.
    Talbot A; Nicholls K; Fletcher JM; Fuller M
    Mol Genet Metab; 2017 Sep; 122(1-2):121-125. PubMed ID: 28847675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long time enzyme replacement therapy stabilizes obstructive lung disease and alters peripheral immune cell subsets in Fabry patients.
    Odler B; Cseh Á; Constantin T; Fekete G; Losonczy G; Tamási L; Benke K; Szilveszter B; Müller V
    Clin Respir J; 2017 Nov; 11(6):942-950. PubMed ID: 26763180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma globotriaosylsphingosine as a biomarker of Fabry disease.
    Togawa T; Kodama T; Suzuki T; Sugawara K; Tsukimura T; Ohashi T; Ishige N; Suzuki K; Kitagawa T; Sakuraba H
    Mol Genet Metab; 2010 Jul; 100(3):257-61. PubMed ID: 20409739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.